Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
about
Clinicoradiological spectrum of reversible splenial lesion syndrome (RESLES) in adults: a retrospective study of a rare entityLevetiracetam in the Treatment of Epileptic Seizures After Liver TransplantationNovel molecular triggers underlie valproate-induced liver injury and its alleviation by the omega-3 fatty acid DHA: role of inflammation and apoptosisAssociation between the blood concentrations of ammonia and carnitine/amino acid of schizophrenic patients treated with valproic acid.Changing incidence of hyperammonemia in Japan from 2006 to 2013: expansion of new antiepileptic drugs reduces the risk of hyperammonemia.Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report.Carnitine and/or Acetylcarnitine Deficiency as a Cause of Higher Levels of AmmoniaGait instability in valproate-treated patients: Call to measure ammonia levels.Valproic acid-induced hyperammonemic encephalopathy in a full-term neonate: a brief review and case report.In response: Commentary on clinical significance of CYP2C9-status-guided valproic acid therapy in children.Risk of Microangiopathy in Patients with Epilepsy under Long-term Antiepileptic Drug Therapy.Hypoxic respiratory failure due to hyperammonemic encephalopathy induced by concurrent use of valproic acid and topiramate, a case report and review of the literature.Valproic acid induced acute liver injury resulting in hepatic encephalopathy- a case report and literature review
P2860
Q36152279-90C737E2-CE0F-44C6-86FA-3CF329C533D5Q36255864-8B57735D-6225-4E51-82A3-A794CDCAD424Q37097358-F578C564-17D8-4676-BBB4-E40DD688B387Q40963325-F56B5357-9904-4F6A-9455-17DA2C086E4FQ41338021-2C02CDF3-39E5-41EE-AF1B-3C360D6FA1B7Q42327075-59E553A2-EA55-4AB3-9473-4560916F3B59Q42646705-B4FC4CFA-8604-4A26-A95F-1CC52B192910Q47784978-95FAD522-197E-48BB-99BF-8A4E312F06FFQ53521796-91413250-CA7E-4851-B120-3B389773F551Q53716299-294FCEAE-185A-4295-A15C-64F508A337F6Q55037428-0A19256E-E6AD-41CA-B1E6-967D3E40FDA0Q55243214-24BD8CC6-BBF5-41B9-8134-4CE4AA5F47D5Q57814899-065FA9B7-3054-43C4-9A9A-CE5395205D5F
P2860
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@ast
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@en
type
label
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@ast
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@en
prefLabel
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@ast
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@en
P2093
P2860
P1433
P1476
Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy
@en
P2093
Cheng-Hsien Lu
Chi-Ren Huang
Chih-Hsiang Lin
Chiung-Chih Chang
Nai-Ching Chen
Wen-Neng Chang
Yan-Ting Lu
Yao-Chung Chuang
Yu-Lung Tseng
P2860
P356
10.1097/MD.0000000000000066
P407
P577
2014-09-01T00:00:00Z